MedCity News April 22, 2020
Life sciences companies are not only under pressure to help identify and make available treatments and vaccines for Covid-19, but they also have an obligation to maintain supply chains for existing treatments and services.
Despite typically high safety stock levels and buffer inventory across the biopharma supply chain, there are signs that the sum and magnitude of supply chain disruptions could impact the industry’s ability to get treatments to patients. In the last two months since the pandemic began, 15 new drugs have been added to the FDA drug shortage list.
Indeed, disruptions have moved from a regional to a global focus. While India recently lifted export bans on many of the active pharmaceutical ingredients (APIs) and raw materials needed...
Today's Sponsors
Today's Sponsor